Please try another search
UMN Pharma Inc. develops and manufactures biopharmaceuticals in Japan and internationally. It is developing UMN-101, a recombinant seasonal influenza vaccine; UMN-102, a recombinant novel influenza vaccine; UMN-103, a recombinant rotavirus vaccine; and UMN-104, a recombinant norovirus vaccine. The company was founded in 2004 and is headquartered in Yokohama, Japan. As of December 12, 2019, UMN Pharma Inc. operates as a subsidiary of Shionogi & Co., Ltd.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review